You are here

  • Home
  • Archive
  • Volume 74, Issue Suppl 2
  • SAT0463 Initial Therapy with an Endothelin Receptor Antagonist (ERA) is Associated with Worse Outcomes in Patients with Systemic Sclerosis and Pulmonary Arterial Hypertension: Observations from the Pulmonary Hypertension Assessment and Recognition of Out…

Article info

Article menu
Download PDFPDF
Poster Presentations
Scleroderma, myositis and related syndromes - clinical aspects and treatment
SAT0463 Initial Therapy with an Endothelin Receptor Antagonist (ERA) is Associated with Worse Outcomes in Patients with Systemic Sclerosis and Pulmonary Arterial Hypertension: Observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort (Pharos)

Authors

Citation

Lammi M, Saketkoo L, Mathai S on behalf of the PHAROS Investigators , et al
SAT0463 Initial Therapy with an Endothelin Receptor Antagonist (ERA) is Associated with Worse Outcomes in Patients with Systemic Sclerosis and Pulmonary Arterial Hypertension: Observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort (Pharos)
Annals of the Rheumatic Diseases 2015;74:828.

Publication history

  • First published June 9, 2015.
Online issue publication 
March 04, 2018

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions